VOLTAS brings ETO sterilization in-house

VOLTAS now offers in-house ethylene oxide sterilization at its ISO 13485-compliant facility in Cottage Grove, Minnesota, aiming to cut validation timelines in half without adding cost. The move gives medical device companies a single on-site path from cleanroom assembly through sterilization, packaging and regulatory support.

Why it matters: - Medical device makers can now keep sterilization, packaging, assembly and documentation under one roof instead of splitting the workflow across outside vendors. - VOLTAS says the in-house model cuts sterilization validation time by 50% compared with outsourced processes, without increasing cost to the customer. - The setup is aimed at single-use devices that cannot withstand heat or radiation-based sterilization.

What happened: - VOLTAS launched in-house ethylene oxide, or ETO, sterilization services at its facility in Cottage Grove, Minnesota. - The company says the service is available now for startups and established device manufacturers. - VOLTAS is offering the service as part of its broader medical device development and manufacturing operation.

The details: - The ISO 13485-compliant facility supports ETO runs from small routine batches to full pallet sterilization. - The service covers development-stage builds and ongoing commercial volumes. - Available services include in-house ETO sterilization, sterile barrier packaging and labeling, sterilization validation and cycle development, cleanroom assembly through sterilization, and regulatory documentation and support. - Device makers can move a product from cleanroom assembly through a validated ETO cycle without leaving the building. - VOLTAS says the in-house process provides full traceability through the entire workflow. - The company supports terminal sterilization for single-use devices, hardest-to-sterilize studies and commercial production. - VOLTAS also says the single-team workflow reduces the coordination burden that comes with managing multiple vendors.

Between the lines: - Bringing ETO in-house can reduce schedule risk because manufacturers are no longer dependent on an external lab’s availability. - The model may also limit transfer errors or documentation gaps that can happen when a device changes hands between separate teams. - VOLTAS is positioning sterilization as one piece of a broader integrated development platform rather than a standalone service.

What's next: - VOLTAS is taking ETO sterilization work from both early-stage companies and established manufacturers. - The company says it will continue pairing sterilization with cleanroom assembly, packaging and regulatory support for submission and audit needs. - More information is available at VOLTAS' website and on the company's LinkedIn page.

The bottom line: - VOLTAS is betting that faster validation, fewer handoffs and one documentation path will make outsourced ETO sterilization easier to replace.